Editorial Standards & Medical Review

Who Writes Our Content

Articles on Houston Weight Loss Directory are written by our editorial team, which includes health writers with backgrounds in medical journalism and patient education. No content on this site is written by clinics or paid advertisers — editorial and advertising are kept strictly separate. Clinics can purchase featured placement in the directory, but they have no input on blog content, clinical information, or how our editorial team covers GLP-1 medications and weight loss treatment.

Our Primary Sources

Every factual claim about medications, clinical outcomes, safety, and FDA policy is sourced from one of the following:

• FDA.gov

  Drug approvals, safety communications, shortage status, and compounding guidance.

• PubMed / peer-reviewed clinical trials

  STEP trials (semaglutide), SURMOUNT trials (tirzepatide), and related obesity medicine research.

• Novo Nordisk and Eli Lilly prescribing information

  Official manufacturer labeling for Wegovy, Ozempic, Zepbound, and Mounjaro.

• Texas Department of Insurance

  State-regulated plan rules and coverage mandates applicable to Texas residents.

• The Obesity Society and ABOM

  Clinical practice guidelines from the American Board of Obesity Medicine and peer obesity medicine organizations.

• Clinic-verified public data

  Hours, addresses, phone numbers, and services verified against clinic websites and public business records.

Medical Review Process

Before publication, each article is reviewed for factual accuracy against the primary sources listed above. Articles covering medication dosing, contraindications, side effects, or FDA regulatory status are cross-checked against the most current available guidance. Our goal is to reflect the actual state of the clinical and regulatory record — not to repeat marketing claims from manufacturers or clinics.

This site does not employ a named physician reviewer at this time. Content is reviewed by our editorial team using the primary source framework described above, and we clearly disclose this. We do not fabricate physician credentials or imply a clinical relationship that does not exist. All articles carry a medical disclaimer directing readers to consult a licensed physician before making treatment decisions.

How We Handle Rapidly Changing Information

GLP-1 medications and compounding regulations are a fast-moving area. FDA shortage status, manufacturer pricing, and insurance coverage rules all change regularly. When we become aware of a material change — such as the FDA removing semaglutide from the shortage list or a major insurer updating its prior authorization policy — we update affected articles and note the revision date. Cost figures and coverage details are estimates based on publicly available information at the time of writing and may not reflect current pricing at any specific clinic.

What We Do Not Do

• —We do not recommend specific medications or clinics for individual patients.
• —We do not accept payment to alter editorial content, rankings, or clinical information.
• —We do not publish testimonials or before/after claims that cannot be verified.
• —We do not reproduce manufacturer marketing as if it were independent clinical assessment.
• —We do not make coverage or reimbursement guarantees — insurance coverage must be verified directly with your plan.

Corrections & Feedback

If you find a factual error in our content or believe a clinic listing is inaccurate, please let us know. We take accuracy seriously and will review and correct verified errors promptly.